Sanofi and Translate Bio to jointly produce mRNA Covid-19 vaccine
Category: #health  By Nikita Chaurasia  Date: 2020-06-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi and Translate Bio to jointly produce mRNA Covid-19 vaccine

French multinational pharmaceutical company Sanofi S.A. is reportedly expanding its collaboration with Translate Bio, a U.S-based mRNA therapeutics company to develop a wide range of messenger ribonucleic acid (mRNA) vaccines against Covid-19. The financial valuation of the new enhanced partnership deal is reported to be USD 2.8 billion.

For those uninitiated, Translate Bio is a leading company that offers mRNA technology which enables human cells to produce specific proteins which help in boosting the immunity system against specific diseases.

Sources close to the matter stated that the deal allows Sanofi to strengthen its position in the race to discover effective and safe vaccine for coronavirus, which has killed around 472,000 people across the globe.

The deal will also provide Sanofi up to 7.2 percent of the Translate Bio’s business as well as exclusive global rights to produce, manufacture, and distribute the vaccine, sources claimed.

Sanofi mentioned in a comment that it expects its mRNA-based Covid-19 vaccine to enter clinical trails by the end of the year, and if successful, will acquire regulatory approval by next year.

Translate Bio will evidently secure an upfront payment of around USD 425 million, which comprises of USD 300 million in cash and stocks worth USD 125 million, sources claimed.

The Massachusetts-based biotech company is also apparently eligible to avail the benefits from further potential milestones as well as other payments of around USD 1.9 billion. According to reliable sources, the deal will make Sanofi the fourth-largest shareholder of Translate Bio.

The two companies are also developing Covid-19 vaccine with Britain’s GlaxoSmithKline, which is expected to receive approval by first half of next year, cite sources.

In other news, China-based Chongqing Zhifei Biological Products publicized that it would soon begin its human trials for recently approved Covid-19 vaccine.

Source Credits –

https://www.straitstimes.com/world/europe/sanofi-in-28b-deal-with-us-firm-to-make-vaccines-amid-virus-fight

https://medcitynews.com/2020/06/sanofi-translate-bio-ramp-up-partnership-on-vaccines-translate-to-receive-up-to-2-3b/?rf=1

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

New research claims sufficiency of vitamin D reduces COVID-19 severity
New research claims sufficiency of vitamin D reduces COVID-19 severity
By Nikita Chaurasia

According to a recent study, COVID-19 patients having sufficient levels of vitamin D, with at least 30 ng/mL of 25-hydroxyvitamin D in their blood, are less likely to witness severe clinical outcomes and deaths. The study, which was published by the...

Amazon adds indoor surveillance drone to security solutions portfolio
Amazon adds indoor surveillance drone to security solutions portfolio
By Nikita Chaurasia

  This is the next big launch after the announcement of car security devices Indoor drone will offer video surveillance in places devoid of static cameras U.S.-based multinational technology giant, Amazon.com Inc. along with Ring Inc. has ...

JPMorgan to move USD 234 billion worth assets to Germany before Brexit
JPMorgan to move USD 234 billion worth assets to Germany before Brexit
By Nikita Chaurasia

  JPMorgan indicated plans to expand its hub in Paris by reassigning services based in London post Brexit The bank plans on completing the migration of its assets to the Frankfurt subsidiary by the end of 2020 As per reliable sources, Amer...